In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Bio-Path Holdings (BPTH), with a price target of $28. The company’s shares closed last Monday at $12.03, close to its 52-week low of $1.61.
Chen commented:
“We believe the study could potentially recruit the sixth evaluable patient and conclude by the end of 2019. As a reminder, prexigebersen is an antisense DNA molecule that blocks expression of growth factor receptor-bound protein 2 (Grb-2). Prexigebersen has shown favorable safety and positive Phase 2 interim data in combination with low-dose cytarabine (LDAC) in elderly patients with AML, demonstrating 65% objective response with a 29% complete response (CR) rate. We expect prexigebersen to demonstrate favorable safety in combination with decitabine as well. In the wake of this update, we reiterate our Buy rating and $28 price target. Triple combo study to start in 2020.”
According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -20.3% and a 28.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Stealth Biotherapeutics Corp, and Aerpio Pharmaceuticals Inc.
Currently, the analyst consensus on Bio-Path Holdings is a Moderate Buy with an average price target of $28.
See today’s analyst top recommended stocks >>
The company has a one-year high of $73.52 and a one-year low of $1.61. Currently, Bio-Path Holdings has an average volume of 163.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline include Prexigebersen, BP1002, and BP1003.